AI coronary plaque analysis and heart disease risk

Coronary artery disease is still the leading cause of death worldwide, and for decades the only reliable way to know whether someone had it was an invasive procedure. That is changing. New tools apply artificial intelligence to CT scans and measure coronary plaque directly, letting clinicians see disease that used to be pure guesswork. In this conversation, an interventional cardiologist explains how AI coronary plaque analysis works and who it can help.

Three ways to look at the coronary arteries

It helps to separate the available tests into three buckets.

• A coronary artery calcium score uses a quick CT scan, without contrast dye, to detect calcium in the arteries. Any calcium means some coronary disease exists.
• A coronary CT angiogram adds intravenous iodine dye and captures detailed images of the artery walls, narrowings and plaque.
• AI coronary plaque analysis takes that angiogram and, using computation and a trained analyst for quality control, returns how much plaque there is, what it is made of and whether blood flow is limited.

The analysis comes back to the clinician in about an hour and a half.

Why symptoms are not enough

Fewer than half of people who have a heart attack had symptoms beforehand. Waiting for chest pain or breathlessness misses most of the disease. Historically, only about a third of patients who underwent an invasive procedure to check for coronary disease actually needed a fix; the other two thirds went through the risk and cost only to be told they were fine. Non-invasive imaging with blood flow analysis, known as FFR, cut that negative invasive rate by roughly two thirds.

Plaque, blood flow and risk

There is no direct link between how much plaque you have and how much your blood flow is restricted. One person can carry a large amount of plaque without any flow limitation; another can have a modest amount in a bad spot that narrows the artery sharply. Blood flow analysis answers whether plaque is limiting flow today and whether a stent might help. The amount and type of plaque, however, speak to long term risk.

Measuring amount and type

The AI analysis reports plaque volume in cubic millimetres and compares it against a population of nearly 300,000 people by age and sex. A 40 year old with a given plaque burden might sit in the 80th percentile, while the same amount in a 70 year old could fall to the 20th. It also distinguishes non-calcified plaque, which carries the higher risk, from calcified plaque. The measurements have been validated prospectively against intravascular ultrasound, the invasive gold standard, on a lesion by lesion basis.

What a calcium score of zero really means

A calcium score of zero does signal very low short term risk, and that is well proven. It does not mean you have no coronary disease, because non-calcified plaque is invisible to a calcium score. Anyone concerned should still understand their risk factors and lipid levels and talk to a physician.

Who benefits most

The specialist highlights several groups:

• Patients with symptoms suggestive of coronary disease, where a CT angiogram is the top ranked test.
• People in high risk occupations, such as pilots and first responders.
• People with a calcium score roughly between 1 and 300, where guidelines leave real ambiguity about how aggressively to treat.
• People who simply want to know their status, understanding they will likely pay out of pocket, since insurance rarely covers this without symptoms.

Tracking change over time

Because the tool is precise, it can follow plaque across scans. In the host's own case, plaque fell by about 40% over 16 months using the same scanner and protocol. A JAMA Cardiology study from Emory University tracked coronary plaque in just 65 men on two prostate cancer drugs and detected a clear difference in progression, something usually impossible with so few patients. On treatment, soft non-calcified plaque turning calcified is generally read as a sign of stabilisation and vascular healing.

Risks and limits

The iodine contrast is benign for most people, and the radiation dose is modest, but it is not zero, so it is worth considering. Cost and access remain barriers, and the test is not yet indicated in guidelines for people without symptoms.

Practical tips

• If you have symptoms, a coronary CT angiogram is the guideline preferred test; talk to your doctor.
• A calcium score of zero is reassuring for risk but does not rule out soft plaque.
• If your calcium score sits in the ambiguous middle range, plaque analysis can clarify how aggressively to treat.
• Use serial scans with the same scanner and protocol to make comparisons meaningful.
• Remember that lowering LDL and ApoB remains the proven way marker toward fewer heart attacks.

Conclusion

AI coronary plaque analysis turns a standard CT scan into a detailed, patient specific picture of disease. It will not replace good clinical judgement, and the outcome evidence is still maturing, but it already helps refine risk, guide treatment and motivate patients in a way that abstract numbers rarely do.